164
Participants
Start Date
February 22, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2028
ABSK112
In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
RECRUITING
Precision NextGen Oncology, Beverly Hills
NOT_YET_RECRUITING
Anhui Chest Hospital, Hefei
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
The first Affiliated Hospital of Xi'an Jiaotong University, Xi'an
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Union Hospital Tongji Medical College Huzhong University of Science and Techology, Wuhan
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
The first Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Central Hospital Affiliated to Shangdong of First Medical University, Jinan
RECRUITING
Shanghai Chest Hospital, Shanghai
NOT_YET_RECRUITING
Sichuan Cancer Hospital, Chengdu
NOT_YET_RECRUITING
Zhejiang Caner Hospital, Hangzhou
Lead Sponsor
Abbisko Therapeutics Co, Ltd
INDUSTRY